文献速递慢病防控与筛查免疫规划卫生政策与健康促进

美国宫颈癌消除的预计时间:一项比较建模研究

Projected time to elimination of cervical cancer in the USA: a comparative modelling study.
PubMed 文献 · Lancet Public Health · 2020-02-10

该建模研究使用哈佛和Policy1-Cervix两个独立开发的宫颈癌微模拟模型,评估美国在现状场景及九种替代的HPV疫苗接种和宫颈筛查扩大场景下HPV所致宫颈癌发病率的变化,以每10万妇女年≤4例为消除阈值。现状下两模型分别预测2038年和2046年达到消除;2020年将筛查覆盖率提升至90%是最有效干预,可提前10-13年消除,2019-2100年间年均避免1400-2088例额外病例。

要点

  • 现状下哈佛模型预测2038年、Policy1-Cervix模型预测2046年宫颈癌发病率降至每10万妇女年≤4例。
  • 2020年将筛查覆盖率提升至90%可提前10-13年消除,年均避免1400-2088例额外病例。
  • HPV疫苗接种覆盖率提升至90%或为26-45岁成人接种对宫颈癌发病率影响相对较小。

核心结论

  • 美国有望在未来二三十年内将宫颈癌作为公共卫生问题消除。
  • 实现更高筛查覆盖率可将消除时间提前10-13年。
  • 针对筛查不足和疫苗接种不足女性的干预仍是实现所有女性宫颈癌消除的关键。

研究设计与样本

  • 比较建模研究,使用哈佛和Policy1-Cervix两个独立开发的宫颈癌微模拟模型。
  • 估计美国HPV所致宫颈癌发病率随时间的变化,包括疫苗接种的群体效应。
  • 比较九种替代的预防性HPV疫苗接种和宫颈筛查扩大场景与现状场景(无额外干预)。
  • 宫颈癌消除阈值定义为每10万妇女年≤4例。
  • 估计2019-2100年间与采用雄心筛查和疫苗接种覆盖率目标相关的可避免宫颈癌病例数。

主要发现

  • 现状假设下,哈佛模型预测宫颈癌发病率到2038年降至每10万妇女年≤4例,Policy1-Cervix模型预测到2046年降至该阈值。
  • 2020年将筛查覆盖率扩大至90%是最有效加快消除的干预,可缩短消除时间10-13年,2019-2100年间年均避免1400-2088例额外病例。
  • 将HPV疫苗接种覆盖率提高至90%或为26-45岁成人接种对宫颈癌发病率影响相对较小。
  • 使用不同人口结构的敏感性分析显示,与现状预测相比,消除时间差异范围为-10年至+27年。

关键数值与推荐

  • 宫颈癌消除阈值:每10万妇女年≤4例。
  • 现状下哈佛模型预测消除时间:2038年;Policy1-Cervix模型预测消除时间:2046年。
  • 筛查覆盖率扩大至90%可缩短消除时间10-13年。
  • 2019-2100年间年均避免额外病例1400-2088例。
  • 敏感性分析中消除时间差异范围:-10年至+27年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 敏感性分析使用不同人口结构导致消除时间与现状预测相比存在差异(范围-10年至+27年)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In May, 2018, the Director-General of WHO issued a global call to eliminate cervical cancer as a public health problem, which will involve ambitious screening and vaccination coverage targets. We aimed to assess the potential for, and timing of, cervical cancer elimination in the USA and whether this could be expedited by adopting ambitious coverage targets, using two cervical cancer simulation models. METHODS: In this modelling study, we used two independently-developed cervical cancer microsimulation models-Harvard and Policy1-Cervix-to estimate changes in the incidence of human papillomavirus (HPV)-induced cervical cancer over time in the USA, including herd effects from vaccination. We compared nine alternative scenarios for prophylactic HPV vaccination and cervical screening scale-up with a status quo scenario that involved no additional interventions in the context of a threshold for cervical cancer elimination of four or fewer cases per 100 000 women-years. We also estimated the number of cervical cancer cases that could be averted between 2019 and 2100 associated with the adoption of ambitious goals for cervical cancer screening and vaccination coverage, and other potential strategies. FINDINGS: Under status quo assumptions, the Havard and Policy1-Cervix models projected that cervical cancer incidence would decrease to less than four or fewer new cases per 100 000 women-years by the 2038 and 2046, respectively. Scaling up screening coverage to 90% in 2020, was the most effective intervention to expedite time to elimination (10-13-year reduction), averting a mean of 1400-2088 additional cases annually between 2019 and 2100. Increasing HPV vaccination coverage to 90% or vaccinating adults aged 26-45 years had relatively little effect on cervical cancer incidence. Sensitivity analysis using different population structures resulted in differences in time to elimination (range -10 years to +27 years) compared with status quo predictions. INTERPRETATION: The USA is on track to eliminate cervical cancer as a public health problem in the next two to three decades. Time to elimination could be expedited by 10-13 years by achieving higher screening coverage. Targeting of underscreened and under-vaccinated women remains key to achieving cervical cancer elimination for all women. FUNDING: US National Cancer Institute.

来源:Lancet Public Health,查看原文。版权归原作者所有。

引用

  1. Burger EA, Smith MA, Killen J, et al. Projected time to elimination of cervical cancer in the USA: a comparative modelling study. Lancet Public Health. 2020. PMID: 32057315. doi:10.1016/S2468-2667(20)30006-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。